Patient Support Services Contact Us
Image: Coherus Investors

News

11/15/21
REDWOOD CITY, Calif. and SHANGHAI, China , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has
11/10/21
REDWOOD CITY, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Nov. 5, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 177,500 shares of
11/08/21
– Key milestones achieved driving near-term commercial product portfolio expansion – – Three BLAs now under FDA review: PD-1 inhibitor toripalimab, biosimilar Lucentis®, biosimilar Humira® – – Multiple additional applications to FDA expected in 2022 – – UDENYCA® delivers 3rd quarter 2021 net sales
11/05/21
REDWOOD CITY, Calif. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end
11/01/21
FDA has granted the toripalimab BLA Priority Review with a target action date of April 2022 REDWOOD CITY, Calif. and SHANGHAI, China , Nov. 01, 2021 (GLOBE NEWSWIRE) --   Coherus BioSciences, Inc.  (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd.
10/29/21
REDWOOD CITY, Calif. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m.
10/11/21
REDWOOD CITY, Calif. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences , Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson . He had been a director of the Company since January 2021 and had previously served as external
10/05/21
- UDENYCA ® On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial - Coherus plans to seek U.S. marketing authorization for the  UDENYCA ®   OBI in 2022 REDWOOD CITY, Calif. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
10/04/21
REDWOOD CITY, Calif. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) today announced that positive results from the pivotal COLUMBUS-AMD clinical trial evaluating and comparing the efficacy and safety between CHS-201 and Lucentis® (ranibizumab) in the
10/01/21
FDA has set a target action date of August 2, 2022 for the CHS-201 BLA REDWOOD CITY, Calif. , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) today announced the United States Food and Drug Administration (FDA) has accepted for review the 351(k) Biologics
09/29/21
REDWOOD CITY, Calif. , Sept. 29, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences , Inc. (Nasdaq: CHRS) announces the passing of board member Samuel Nussbaum , M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and
09/24/21
REDWOOD CITY, Calif. , Sept. 24, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Sept. 22, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 229,500 shares
09/16/21
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with ESCC – - Coherus and Junshi Biosciences plan to submit a BLA supplement for 1L ESCC in
09/15/21
- Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma - REDWOOD CITY, Calif. , and SHANGHAI, China , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd
09/13/21
REDWOOD CITY, Calif. and SHANGHAI, China , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study
09/10/21
REDWOOD CITY, Calif. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23 rd Annual H.C. Wainwright Global Investment Conference . The presentation will be made available at 7 a.m.
09/08/21
REDWOOD CITY, Calif. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and   September 17 at
09/01/21
SHANGHAI, China , and REDWOOD CITY, Calif. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of the Biologics
08/27/21
REDWOOD CITY, Calif. , Aug. 27, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Aug. 26, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 278,000 shares of
08/18/21
– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone   – - Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC - - Study to be presented September 13 at IASLC 2021 World Conference on
08/12/21
–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA– SHANGHAI, China , and REDWOOD CITY, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and
08/05/21
–1 st line nasopharyngeal indication and 2 nd /3 rd line indications to be concurrently submitted 3Q 2021  in the toripalimab BLA — – CHS-201 (Lucentis® biosimilar) BLA submitted to FDA – –CHS-1420 (Humira® biosimilar) BLA review progressing with December target action date – – Second quarter 2021
07/26/21
REDWOOD CITY, Calif. , July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021 . Starting at 5 p.m.
07/21/21
- Csiki has over two decades of experience in research and drug development of cancer immunotherapies - REDWOOD CITY, Calif. , July 21, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of Ildiko Csiki , M.D., Ph.D., a leader in the field
07/12/21
REDWOOD CITY, Calif. , July 12, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of
06/04/21
– Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET – SHANGHAI, China , and REDWOOD CITY, Calif. , June 04, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc.
06/03/21
– In pivotal Phase 3 JUPITER-02 study, toripalimab plus chemotherapy significantly improved PFS compared to chemotherapy alone in high and low PD-L1 expression subgroups – –  Although median overall survival (OS) analysis was not yet mature, a 40% reduction in risk of death was observed in the
05/07/21
REDWOOD CITY, Calif. , May 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST .
05/06/21
– Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session – –Toripalimab is one of four additional Coherus product
04/30/21
REDWOOD CITY, Calif. , April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 28, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 483,000 shares
04/30/21
REDWOOD CITY, Calif. , April 30, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021 . Starting at 4:30 p.m.
04/29/21
- Toripalimab data will also be featured in ASCO’s official press program - SHANGHAI, China , and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co. , Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and  Coherus BioSciences, Inc.  (“Coherus”, Nasdaq:
04/23/21
REDWOOD CITY, Calif. , April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1
04/20/21
Coherus received $50 million from sale of 2,491,998 shares at $20.06 per share REDWOOD CITY, Calif. , April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences.
03/03/21
- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China , and REDWOOD CITY, Calif. , March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc.
02/25/21
REDWOOD CITY, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. 41 st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m.
02/24/21
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 -  - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year -  - Pipeline progress with CHS-1420 (adalimumab biosimilar) BLA
02/18/21
REDWOOD CITY, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021.
02/17/21
REDWOOD CITY, Calif. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira®
02/16/21
REDWOOD CITY, Calif. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity.
02/02/21
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic
02/01/21
- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody - First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation - Options to PD-1 combination agents, TIGIT and IL-2,
01/22/21
REDWOOD CITY, Calif. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares
01/07/21
REDWOOD CITY, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021 .  “We are excited to welcome Alan and Mark to the Coherus
01/05/21
REDWOOD CITY, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST .